TY - JOUR
T1 - 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study)
T2 - A Multicenter, International, Randomized Double-Blind Trial
AU - Blackwell, Sean C.
AU - Chauhan, Suneet P.
AU - Gyamfi-Bannerman, Cynthia
AU - Biggio, Joseph R.
AU - Hughes, Brenna L.
AU - Louis, Judette M.
AU - Manuck, Tracy A.
AU - Miller, Hugh S.
AU - Das, Anita F.
AU - Saade, George R.
AU - Nielsen, Peter
AU - Baker, Jeff
AU - Yuzko, Oleksandr M.
AU - Reznichenko, Galyna I.
AU - Reznichenko, Nataliya Y.
AU - Pekarev, Oleg
AU - Tatarova, Nina
AU - Gudeman, Jennifer
AU - Duncan, Monique
AU - Williams, Laura
AU - Krop, Julie
AU - Birch, Robert
AU - Jozwiakowski, Michael J.
N1 - Funding Information:
This study was funded by AMAG Pharmaceuticals, 1100 Winter Street Waltham, MA 02451.
Funding Information:
P.N., J.B., O.M.Y., G.I.R., N.Y.R., O.P., N.T. are PROLONG clinical site investigators. C.G.-B. and J.R.B. have received grant funding for other project(s) from the sponsor (AMAG Pharmaceuticals, Inc.). G.R.S. and H.S.M. have received consulting fees from AMAG Pharmaceuticals, Inc. A.F.D. has received consulting/personal fees related to her work on the project from the sponsor (AMAG Pharmaceuticals, Inc.). J.G., R.B., M.J.J., M.D., L.W., J.K. are current or former employees of AMAG Pharmaceuticals, Inc.
PY - 2020
Y1 - 2020
N2 - Background âwomen with a history of spontaneous preterm birth (SPTB) are at a significantly increased risk for recurrent preterm birth (PTB). To date, only one large U.S. clinical trial comparing 17-OHPC (17-α-hydroxyprogesterone caproate or 17P) to placebo has been published, and this trial was stopped early due to a large treatment benefit. Objective âThis study aimed to assess whether 17-OHPC decreases recurrent PTB and neonatal morbidity in women with a prior SPTB in a singleton gestation. Study Design âThis was a double-blind, placebo-controlled international trial involving women with a previous singleton SPTB (clinicaltrials.gov: NCT 01004029). Women were enrolled at 93 clinical centers (41 in the United States and 52 outside the United States) between 16 0/7 to 20 6/7 weeks in a 2:1 ratio, to receive either weekly intramuscular (IM) injections of 250 mg of 17-OHPC or an inert oil placebo; treatment was continued until delivery or 36 weeks. Co-primary outcomes were PTB < 35 weeks and a neonatal morbidity composite index. The composite included any of the following: Neonatal death, grade 3 or 4 intraventricular hemorrhage, respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis, or proven sepsis. A planned sample size of 1,707 patients was estimated to provide 98% power to detect a 30% reduction in PTB < 35 weeks (30% to 21%) and 90% power to detect a 35% reduction in neonatal composite index (17%-11%) using a two-sided type-I error of 5%. Finally, this sample size would also provide 82.8% power to rule out a doubling in the risk of fetal/early infant death assuming a 4% fetal/early infant death rate. Analysis was performed according to the intention-to-treat principle. Results âaseline characteristics between the 1,130 women who received 17-OHPC and 578 women who received placebo were similar. Overall, 87% of enrolled women were Caucasian, 12% had >1 prior SPTB, 7% smoked cigarettes, and 89% were married/lived with partner. Prior to receiving study drug, 73% women had a transvaginal cervical length measurement performed and <2% had cervical shortening <25 mm. There were no significant differences in the frequency of PTB < 35 weeks (17-OHPC 11.0% vs. placebo 11.5%; relative risk = 0.95 [95% confidence interval (CI): 0.71-1.26]) or neonatal morbidity index (17-OHPC 5.6% vs. placebo 5.0%; relative risk = 1.12 [95% CI: 0.68-1.61]). There were also no differences in frequency of fetal/early infant death (17-OHPC 1.7% vs. placebo 1.9%; relative risk = 0.87 [95% CI: 0.4-1.81]. Maternal outcomes were also similar. In the subgroup of women enrolled in the United States (n = 391; 23% of all patients), although the rate of PTB < 35 weeks was higher than the overall study population, there were no statistically significant differences between groups (15.6% vs. 17.6%; relative risk = 0.88 [95% CI: 0.55, 1.40]. Conclusion âin this study population, 17-OHPC did not decrease recurrent PTB and was not associated with increased fetal/early infant death.
AB - Background âwomen with a history of spontaneous preterm birth (SPTB) are at a significantly increased risk for recurrent preterm birth (PTB). To date, only one large U.S. clinical trial comparing 17-OHPC (17-α-hydroxyprogesterone caproate or 17P) to placebo has been published, and this trial was stopped early due to a large treatment benefit. Objective âThis study aimed to assess whether 17-OHPC decreases recurrent PTB and neonatal morbidity in women with a prior SPTB in a singleton gestation. Study Design âThis was a double-blind, placebo-controlled international trial involving women with a previous singleton SPTB (clinicaltrials.gov: NCT 01004029). Women were enrolled at 93 clinical centers (41 in the United States and 52 outside the United States) between 16 0/7 to 20 6/7 weeks in a 2:1 ratio, to receive either weekly intramuscular (IM) injections of 250 mg of 17-OHPC or an inert oil placebo; treatment was continued until delivery or 36 weeks. Co-primary outcomes were PTB < 35 weeks and a neonatal morbidity composite index. The composite included any of the following: Neonatal death, grade 3 or 4 intraventricular hemorrhage, respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis, or proven sepsis. A planned sample size of 1,707 patients was estimated to provide 98% power to detect a 30% reduction in PTB < 35 weeks (30% to 21%) and 90% power to detect a 35% reduction in neonatal composite index (17%-11%) using a two-sided type-I error of 5%. Finally, this sample size would also provide 82.8% power to rule out a doubling in the risk of fetal/early infant death assuming a 4% fetal/early infant death rate. Analysis was performed according to the intention-to-treat principle. Results âaseline characteristics between the 1,130 women who received 17-OHPC and 578 women who received placebo were similar. Overall, 87% of enrolled women were Caucasian, 12% had >1 prior SPTB, 7% smoked cigarettes, and 89% were married/lived with partner. Prior to receiving study drug, 73% women had a transvaginal cervical length measurement performed and <2% had cervical shortening <25 mm. There were no significant differences in the frequency of PTB < 35 weeks (17-OHPC 11.0% vs. placebo 11.5%; relative risk = 0.95 [95% confidence interval (CI): 0.71-1.26]) or neonatal morbidity index (17-OHPC 5.6% vs. placebo 5.0%; relative risk = 1.12 [95% CI: 0.68-1.61]). There were also no differences in frequency of fetal/early infant death (17-OHPC 1.7% vs. placebo 1.9%; relative risk = 0.87 [95% CI: 0.4-1.81]. Maternal outcomes were also similar. In the subgroup of women enrolled in the United States (n = 391; 23% of all patients), although the rate of PTB < 35 weeks was higher than the overall study population, there were no statistically significant differences between groups (15.6% vs. 17.6%; relative risk = 0.88 [95% CI: 0.55, 1.40]. Conclusion âin this study population, 17-OHPC did not decrease recurrent PTB and was not associated with increased fetal/early infant death.
KW - 17-HPC
KW - 17-OHPC
KW - 17-P
KW - 17-hydroxyprogesterone caproate
KW - preterm birth
KW - progestogens
KW - recurrent preterm birth
KW - spontaneous preterm birth
UR - http://www.scopus.com/inward/record.url?scp=85078271848&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078271848&partnerID=8YFLogxK
U2 - 10.1055/s-0039-3400227
DO - 10.1055/s-0039-3400227
M3 - Article
C2 - 31652479
AN - SCOPUS:85078271848
VL - 37
SP - 127
EP - 136
JO - American Journal of Perinatology
JF - American Journal of Perinatology
SN - 0735-1631
IS - 2
ER -